SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or
15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): January 1996
BIOPHARMACEUTICS, INC.
(Exact name of Registrant as specified in its Charter)
DELAWARE 1-9370 13-3186327
(State or other (Commission File Number) (I.R.S Employer
jurisdiction of I.D. Number)
incorporation)
990 Station Road
Bellport, New York 11713
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (516)286-5800
N/A
(Former name or former address, if changed since last report.)
1
<PAGE>
ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS
On January 4, 1996 the Company signed a Letter of Intent to purchase
three branded consumer product lines of London International US Holdings, Inc.
for the sum of $3,600,000. The purchase includes all trade names, trademarks,
patents and all saleable finished goods inventory related to the Feminine
Hygiene Business. Each of the product lines has been marketed in the United
States for the past ten years.
The Company is presently arranging for financing to complete the
acquisition by March 1996. The agreement in principle is also subject to a
formal agreement to be executed by the parties.
ITEM 6. RESIGNATION OF REGISTRANT'S DIRECTOR
Dr. Alfred Stracher resigned from the Board of Directors of
Biopharmaceutics, Inc. as of December 4, 1995.
EXHIBIT INDEX
Current Report on Form 8-K
of
Biopharmaceutics, Inc.
Date of Report: January 18, 1996
Exhibits:
28.10 Letter of Intent dated January 4, 1996
28.11 Letter of Resignation dated December 4, 1995
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOPHARMACEUTICS, INC.
(Registrant)
By: /s/ Edward Fine
Edward Fine
---------------------
President, Chief Executive Officer
(Signature)
Dated: January 18, 1996
3
<PAGE>
